DOUBLE-BLIND COMPARISON OF DOXAZOSIN AND ENALAPRIL IN PATIENTS WITH MILD OR MODERATE ESSENTIAL-HYPERTENSION

被引：20

作者：

WESSELS, F

机构：

来源：

AMERICAN HEART JOURNAL | 1991年 / 121卷 / 01期

关键词：

D O I：

10.1016/0002-8703(91)90862-C

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The antihypertensive efficacy and safety of doxazosin and enalapril were compared in the general practice setting (n = 54). Both agents produced comparable, statistically significant (p < 0.05) reductions in mean blood pressure with no clinically relevant changes in heart rate. Side effects in the two groups were mild or moderate and disappeared or were tolerated with continued treatment. Doxazosin, in contrast to enalapril, produced a significant (p < 0.05) reduction in the total serum cholesterol concentration, a reduction in the level of triglycerides, and a favorable increase in the high-density lipoprotein/total cholesterol ratio. The reduction in calculated coronary heart disease risk produced by doxazosin (-27.58%) was highly significant (p < 0.0002) and greater than that produced by enalapril (-18.49% p < 0.02).

引用

收藏

页码：299 / 303

页数：5

相关论文

共 21 条

[1] DOXAZOSIN IN PATIENTS WITH HYPERTENSION [J].

CONRAD, KA ;

FAGAN, TC ;

MACKIE, MJ ;

MAYSHAR, PV ;

LEE, S ;

SOUHRADA, JF ;

FALKNER, FC ;

LAZAR, JD .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 35 (01) :21-24

[2] THE ANTIHYPERTENSIVE EFFECTS OF DOXAZOSIN - A CLINICAL OVERVIEW [J].

COX, DA ;

LEADER, JP ;

MILSON, JA ;

SINGLETON, W .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 21 :S83-S90

[3] EFFECT OF DOXAZOSIN MONOTHERAPY ON BLOOD-PRESSURE AND PLASMA-LIPIDS IN PATIENTS WITH ESSENTIAL-HYPERTENSION [J].

CUBEDDU, LX ;

POOL, JL ;

BLOOMFIELD, R ;

KLOTMAN, PE ;

PICKERING, BI ;

WOMBOLT, DG ;

NELSON, EB ;

HALPERIN, A .

AMERICAN JOURNAL OF HYPERTENSION, 1988, 1 (02) :158-167

[4]

DELEEUW PW, 1982, EUR J CLIN PHARMACOL, V23, P379

[5]

DISTLER A, 1988, DTSCH ARZTEBL, V85, P1855

[6] A PHARMACODYNAMIC AND PHARMACOKINETIC ASSESSMENT OF A NEW ALPHA-ADRENOCEPTOR ANTAGONIST, DOXAZOSIN (UK33274) IN NORMOTENSIVE SUBJECTS [J].

ELLIOTT, HL ;

MEREDITH, PA ;

SUMNER, DJ ;

MCLEAN, K ;

REID, JL .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1982, 13 (05) :699-703

[7] CLINICAL PHARMACOLOGICAL STUDIES WITH DOXAZOSIN [J].

ELLIOTT, HL ;

MEREDITH, PA ;

VINCENT, J ;

REID, JL .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 21 :S27-S31

[8] SERUM-LIPID CHANGES IN A ONE-YEAR, MULTICENTER, DOUBLE-BLIND COMPARISON OF DOXAZOSIN AND ATENOLOL FOR MILD TO MODERATE ESSENTIAL-HYPERTENSION [J].

FRICK, MH ;

COX, DA ;

HIMANEN, P ;

HUTTUNEN, M ;

PITKAJARVI, T ;

PORSTI, P ;

POYHONEN, L ;

PYYKONEN, ML ;

REINKAINEN, P ;

SALMELA, P ;

SARASTE, M .

AMERICAN JOURNAL OF CARDIOLOGY, 1987, 59 (14) :G61-G67

[9] A LONG-TERM DOUBLE-BLIND COMPARISON OF DOXAZOSIN AND ATENOLOL IN PATIENTS WITH MILD TO MODERATE ESSENTIAL-HYPERTENSION [J].

FRICK, MH ;

HALTTUNEN, P ;

HIMANEN, P ;

HUTTUNEN, M ;

PORSTI, P ;

PITKAJARVI, T ;

POYHONEN, L ;

PYYKONEN, ML ;

REINIKAINEN, P ;

SALMELA, P ;

SARASTE, M .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 21 :S55-S62

[10]

HORDER MH, 1988, MUNCHEN MED WOCHEN, V130, P819